Puma Biotechnology Inc (NASDAQ: PBYI) on Monday, plunged -6.41% from the previous trading day, before settling in for the closing price of $3.12. Within the past 52 weeks, PBYI’s price has moved between $2.22 and $7.73.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -0.59%. The company achieved an average annual earnings per share of -33.33%. With a float of $34.85 million, this company’s outstanding shares have now reached $49.07 million.
The extent of productivity of a business whose workforce counts for 185 workers is very important to gauge. In terms of profitability, gross margin is 69.29%, operating margin of 13.3%, and the pretax margin is 10.13%.
Puma Biotechnology Inc (PBYI) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Puma Biotechnology Inc is 29.01%, while institutional ownership is 54.36%. The most recent insider transaction that took place on Aug 12 ’24, was worth 81,466. In this transaction Director of this company sold 23,358 shares at a rate of $3.49, taking the stock ownership to the 47,000 shares. Before that another transaction happened on Aug 12 ’24, when Company’s Director proposed sale 23,358 for $3.76, making the entire transaction worth $87,826.
Puma Biotechnology Inc (PBYI) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -33.33% per share during the next fiscal year.
Puma Biotechnology Inc (NASDAQ: PBYI) Trading Performance Indicators
Puma Biotechnology Inc (PBYI) is currently performing well based on its current performance indicators. A quick ratio of 1.40 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.59. Likewise, its price to free cash flow for the trailing twelve months is 4.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.47, a number that is poised to hit 0.09 in the next quarter and is forecasted to reach 0.34 in one year’s time.
Technical Analysis of Puma Biotechnology Inc (PBYI)
The latest stats from [Puma Biotechnology Inc, PBYI] show that its last 5-days average volume of 0.46 million was inferior to 0.47 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 20.59%. Additionally, its Average True Range was 0.23.
During the past 100 days, Puma Biotechnology Inc’s (PBYI) raw stochastic average was set at 36.48%, which indicates a significant decrease from 39.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.42% in the past 14 days, which was lower than the 85.27% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.89, while its 200-day Moving Average is $3.72. Now, the first resistance to watch is $3.11. This is followed by the second major resistance level at $3.30. The third major resistance level sits at $3.40. If the price goes on to break the first support level at $2.82, it is likely to go to the next support level at $2.72. The third support level lies at $2.53 if the price breaches the second support level.
Puma Biotechnology Inc (NASDAQ: PBYI) Key Stats
Market capitalization of the company is 143.34 million based on 49,088K outstanding shares. Right now, sales total 235,640 K and income totals 21,590 K. The company made 80,540 K in profit during its latest quarter, and 20,320 K in sales during its previous quarter.
